Search results
Results from the WOW.Com Content Network
Thrombin (Factor IIa) (EC 3.4.21.5, fibrose, thrombase, thrombofort, topical, thrombin-C, tropostasin, activated blood-coagulation factor II, E thrombin, beta-thrombin, gamma-thrombin) is a serine protease, that converts fibrinogen into strands of insoluble fibrin, as well as catalyzing many other coagulation-related reactions.
Direct thrombin inhibitors (DTIs) are a class of medication that act as anticoagulants (delaying blood clotting) by directly inhibiting the enzyme thrombin (factor IIa). Some are in clinical use, while others are undergoing clinical development.
Coagulation factor concentrates are used to treat hemophilia, to reverse the effects of anticoagulants, and to treat bleeding in people with impaired coagulation factor synthesis or increased consumption. Prothrombin complex concentrate, cryoprecipitate and fresh frozen plasma are commonly used coagulation factor products.
Coagulation activation markers are biomarkers of net activation of coagulation and fibrinolysis. [ 1 ] [ 2 ] Examples include prothrombin fragment 1+2 (F1+2), thrombin–antithrombin complex (TAT), fibrinopeptide A (FpA), fibrin monomers (FMs), plasmin-α 2 -antiplasmin complex (PAP), activated protein C–protein C inhibitor (APC-PCI), and D ...
Prothrombin G20210A is a genotypic trait that provides a prompter coagulation response. It increases the risk of blood clots including from deep vein thrombosis , and of pulmonary embolism . [ 1 ] One copy of the mutation increases the risk of a blood clot from 1 in 1,000 per year to 2.5 in 1,000. [ 1 ]
Unlike AT activated by heparin, AT activated by LMWH cannot inhibit thrombin (factor IIa) but can only inhibit clotting factor Xa. The effects of LMWHs cannot be acceptably measured using the partial thromboplastin time (PTT) or activated clotting time (ACT) tests. [16]
Antithrombin (AT) is a small glycoprotein that inactivates several enzymes of the coagulation system. It is a 464-amino-acid protein produced by the liver.It contains three disulfide bonds and a total of four possible glycosylation sites. α-Antithrombin is the dominant form of antithrombin found in blood plasma and has an oligosaccharide occupying each of its four glycosylation sites.
Thrombin (factor IIa in the coagulation cascade) is a clotting factor that converts fibrinogen into fibrin, which then polymerizes to form a blood clot. Under ultrasound guidance, thrombin can be injected directly into a pseudoaneurysm, causing it to clot.